Aptinyx to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021

Rhea-AI Summary

Aptinyx Inc. (NASDAQ: APTX) will host a conference call on November 9, 2021, at 5:00 p.m. ET to discuss its third quarter 2021 financial results and recent developments. Interested parties can participate by dialing (844) 200 6205 (domestic) or (929) 526 1599 (international) with conference ID 322632. The call will also be available via live audio webcast on the company's website, with a replay accessible for 30 days post-event. Aptinyx focuses on developing innovative therapies for brain and nervous system disorders, with several candidates in clinical development.

Positive

• Aptinyx is advancing three product candidates targeting chronic pain, PTSD, and cognitive impairment.
• The company continues to develop its proprietary discovery platform for small-molecule NMDA receptor modulators.

Negative

• None.

EVANSTON, Ill--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 9, 2021 at 5:00 p.m. ET to report third quarter 2021 financial results and discuss recent business highlights.

To access the live conference call, please dial (844) 200 6205 (domestic) or (929) 526 1599 (international) and refer to conference ID 322632. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com or follow Aptinyx on Twitter @Aptinyx.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005281/en/

Investor & Media Contact:

Patrick Flavin

Aptinyx Inc.

ir@aptinyx.com or corporate@aptinyx.com

847-871-0377

Source: Aptinyx Inc.

FAQ

When will Aptinyx report its Q3 2021 financial results?

Aptinyx will report its Q3 2021 financial results on November 9, 2021, at 5:00 p.m. ET.

How can I access the Aptinyx Q3 2021 earnings call?

You can access the call by dialing (844) 200 6205 for domestic calls or (929) 526 1599 for international calls.

What is the focus of Aptinyx's research and development?

Aptinyx focuses on developing therapies for brain and nervous system disorders, with a proprietary platform for discovering NMDA receptor modulators.

What are the main product candidates being developed by Aptinyx?

Aptinyx is developing product candidates for chronic pain, post-traumatic stress disorder (PTSD), and cognitive impairment.